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INTRODUCTION: The effectiveness of high-frequency oscillatory ventilation (HFOV) in the pe-
diatric hematopoietic cell transplant patient has not been established. We sought to identify current
practice patterns of HFOV, investigate parameters during HFOV and their association with mor-
tality, and compare the use of HFOV to conventional mechanical ventilation in severe pediatric
ARDS. METHODS: This is a retrospective analysis of a multi-center database of pediatric and
young adult allogeneic hematopoietic cell transplant subjects requiring invasive mechanical venti-
lation for critical illness from 2009 through 2014. Twelve United States pediatric centers contrib-
uted data. Continuous variables were compared using a Wilcoxon rank-sum test or a Kruskal-
Wallis analysis. For categorical variables, univariate analysis with logistic regression was performed.
RESULTS: The database contains 222 patients, of which 85 subjects were managed with HFOV. Of
this HFOV cohort, the overall pediatric ICU survival was 23.5% (n  20). HFOV survivors were
transitioned to HFOV at a lower oxygenation index than nonsurvivors (25.6, interquartile range
21.1–36.8, vs 37.2, interquartile range 26.5–52.2, P  .046). Survivors were transitioned to HFOV
earlier in the course of mechanical ventilation, (day 0 vs day 2, P  .002). No subject survived who
was transitioned to HFOV after 1 week of invasive mechanical ventilation. We compared
subjects with severe pediatric ARDS treated only with conventional mechanical ventilation
versus early HFOV (within 2 d of invasive mechanical ventilation) versus late HFOV. There was
a trend toward difference in survival (conventional mechanical ventilation 24%, early HFOV
30%, and late HFOV 9%, P  .08). CONCLUSIONS: In this large database of pediatric
allogeneic hematopoietic cell transplant subjects who had acute respiratory failure requiring
invasive mechanical ventilation for critical illness with severe pediatric ARDS, early use of
HFOV was associated with improved survival compared to late implementation of HFOV, and
the subjects had outcomes similar to those treated only with conventional mechanical ventila-
tion. Key words: hematopoietic stem cell transplantation; critical care; respiratory insufficiency;
artificial respiration; high frequency ventilation; mortality; respiratory distress syndrome; adult.
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Introduction
The pediatric allogeneic hematopoetic cell transplant
patient admitted to the pediatric ICU has a high mortality
risk. While outcomes for these patients have improved,1
respiratory failure and mechanical ventilation continue to
be associated with high mortality.2-5 These patients are at
high risk of severe pulmonary complications when re-
spiratory failure develops.6-8 Immunodeficiency is a risk
factor for the development of pediatric ARDS and re-
lated mortality. The vast majority of pediatric hemato-
poietic cell transplant patients intubated for respiratory
failure develop pediatric ARDS within the first week of
ventilation.9
High-frequency oscillatory ventilation (HFOV) is a com-
mon rescue modality utilized in pediatric ARDS. Data
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supporting its use in pediatric ARDS demonstrate an im-
provement in oxygenation.10-14 However, emerging data
question the effect of HFOV on meaningful outcomes.
Some studies have suggested that HFOV use may be as-
sociated with a higher mortality and a longer duration of
ventilation even when severity of illness markers are in-
corporated into the analyses.15,16 In the adult population,
HFOV use has been found to not improve survival. One
trial was stopped early due to a higher mortality rate,
increased sedation and neuromuscular blockade, and more
vasoactive agents in the HFOV group. In pediatrics, un-
fortunately, the available data do not allow for an evi-
dence-based application of HFOV in the management of
pediatric ARDS. Furthermore, the effectiveness of HFOV
in unique and highly vulnerable populations, such as pe-
diatric hematopoietic cell transplant patients, has not been
established.
We sought to establish current practice patterns of HFOV
in the pediatric allogeneic hematopoietic cell transplant
patient, investigate parameters during HFOV and their as-
sociation with mortality, and compare HFOV use to con-
ventional mechanical ventilation in patients with severe
pediatric ARDS.
Methods
This is a secondary analysis of a retrospective multi-
center database. Twelve centers contributed up to 25 of
their most recent, consecutive, pediatric allogeneic hema-
topoietic cell transplant patients who had acute respiratory
failure requiring invasive mechanical ventilation. All in-
dications for allogeneic hematopoietic cell transplant were
included. Subjects were included if they were between the
ages of 1 month and 21 y. Autologous transplant patients
were excluded. Patients who were admitted prior to Jan-
uary 1, 2009, were also excluded from the study to
ensure the data would be as relevant to current practice
as possible. Institutional review board approval was ob-
tained at each individual center prior to the start of data
collection.
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Although high-frequency oscillatory ventilation
(HFOV) is commonly used in pediatric ARDS, the ef-
fectiveness of this modality remains unclear. Many stud-
ies suggest an improvement in oxygenation, yet other
studies suggest its use may be associated with higher
mortality and longer duration of ventilation. The cur-
rently available data do not allow for an evidence-based
application of HFOV. Furthermore, the application of
HFOV in the pediatric hematopoietic cell transplant
patient has not been established.
What this paper contributes to our knowledge
In pediatric and young adults after hematopoietic cell
transplant with severe pediatric ARDS, those who sur-
vived had continued improvement in oxygenation
throughout an HFOV course. Also, earlier use of HFOV
was associated with improved survival compared to
those who were transitioned later in the course of me-
chanical ventilation. Late transition to HFOV, espe-
cially after 7 d of mechanical ventilation, should be
done with caution.
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The study was performed at the following institutions:
Riley Hospital for Children at Indiana University School
of Medicine; Joseph M Sanzari Children’s Hospital at Hack-
ensack University Medical Center; Medical College of Wis-
consin, Children’s Hospital of Wisconsin; Children’s Hos-
pital of Philadelphia University of Pennsylvania Perelman
School of Medicine; University of Minnesota, Masonic
Children’s Hospital; Weil Cornell Medical College, New
York Presbyterian Hospital; Dana-Farber Cancer Institute;
Children’s Hospital of Los Angeles; University of Wash-
ington and Seattle Children’s Hospital; Duke Children’s
Hospital; Nationwide Children’s Hospital; and Penn State
Children’s Hospital.
A total of 222 patients were included in the original
database, of which 85 subjects received HFOV at some
point during their course of mechanical ventilation. These
patients served as the subjects for the description of
HFOV utilization in this population as well as for the
comparison of survivors to nonsurvivors. We collected
the following data points: demographics, transplant vari-
ables, length of pediatric ICU stay, duration of mechan-
ical ventilation, duration of HFOV, use of vasoactive
agents during the course of mechanical ventilation, use
of renal replacement therapy during the course of me-
chanical ventilation, use of inhaled nitric oxide, respi-
ratory infections, and survival. Respiratory parameters,
settings, and arterial blood gas data were collected ev-
ery 6 h for the day before, the day of, and day after
transition to HFOV. Oxygenation index (OI) was cal-
culated as (FIO2  P aw/PaO2)  100, where P aw indicates
mean airway pressure. Oxygen saturation index was cal-
culated as (FIO2  P aw/PaO2)  100 if the pulse oximeter
saturation was  97%.17
All but 2 of the subjects had severe pediatric ARDS as
defined using the OI or oxygen saturation index criteria
established by the Pediatric Acute Lung Injury and Con-
sensus Conference (PALICC); to assess the value of tim-
ing of HFOV, subjects were categorized into 3 groups:
subjects managed only with conventional mechanical ven-
tilation, subjects placed on HFOV early in the course of
mechanical ventilation, and subjects transitioned to HFOV
late in the mechanical ventilation course. Early HFOV was
defined a priori as being transitioned to HFOV by day 2 of
mechanical ventilation, with the day of intubation being
day 0.
Statistical Analysis
Continuous variables are presented as medians with in-
terquartile ranges (IQRs) and were compared with a Wil-
coxon rank-sum test or a Kruskal-Wallis analysis. A Dunn
test was run to conduct a pairwise comparison for vari-
ables that were statistically significant on a Kruskal-Wallis
analysis when comparing the 3 groups of conventional
mechanical ventilation, early HFOV, and late HFOV. Cat-
egorical variables are presented as frequencies or percent-
ages and were compared with chi-square analysis or a
Fisher exact test where appropriate.
Results
There were 85 pediatric hematopoietic cell transplant
subjects transitioned to HFOV. Of these 85 subjects, only
20 subjects survived to pediatric ICU discharge for an
overall survival rate of 23.5%. At 180 d after pediatric
ICU discharge, only 14 of the 20 subjects were still alive,
rendering a 180-d survival rate of 16.5% for the whole
HFOV cohort. Demographics and those categorized by
survival are displayed in Table 1. Of note, survivors were
more likely to be female (P  .047). Interestingly, there
was a predominance of acute lymphoblastic leukemia in
the group that survived compared to those who died (50%
vs 20%, P  .008). Of the 20 surviving subjects, 10 had
acute lymphoblastic leukemia as the indication for trans-
plant. While not reaching statistical significance, it is of
note that none of the subjects with hemophagocytic lym-
phohistiocytosis survived a course of HFOV. There were
no differences in any of the other underlying diagnoses
between survivors and nonsurvivors. When underlying di-
agnoses were categorized as oncologic or non-oncologic,
there was also no difference between survivors and non-
survivors (P  .13).
The initial HFOV settings can be found in Table 2. The
median change in P aw between the 6 h prior to HFOV
initiation and the implementation of HFOV was an in-
crease of 10.5 cm H2O, and this was not different between
survivors and nonsurvivors.
Subjects who survived were transitioned to HFOV at a
lower OI (25.6, IQR 21.1–36.8 vs 37.2, IQR 26.5–52.2,
P  .046). The median OI at 6 h and 24 h of HFOV for
both survivors and nonsurvivors decreased. The median
OI at 48 h for the survivors was lower than that for non-
survivors (P  .02). Additionally, the median OI for non-
survivors was almost the same at 24 h, 48 h, and at dis-
continuation of HFOV (Table 3).
Survivors were transitioned to HFOV earlier in the course
of mechanical ventilation. Their median day of transition
from conventional mechanical ventilation to HFOV was
0 d (IQR 0–1.5) versus 2 d (IQR 0–9) for nonsurvivors,
P  .002. Table 4 illustrates common critical care inter-
ventions by survival status. Seventeen of the 20 survivors
were transitioned by day 2 of invasive mechanical venti-
lation. Those transitioned to HFOV early had a higher
survival than those transitioned late (32.7% [n  17] vs
9.1% [n 3], P .02). No subjects who were transitioned
to HFOV after 1 week of conventional mechanical venti-
lation survived.
HFOV USE IN PEDIATRIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS
406 RESPIRATORY CARE • APRIL 2018 VOL 63 NO 4
There was no difference between survivors and nonsur-
vivors in the need for vasoactive agents or renal replace-
ment therapy. Nonsurvivors were more likely to have been
placed on inhaled nitric oxide (P  .007) (Table 4). The
institutional effect for this population was also examined,
and no institutional effect on mortality was found (P .41).
In addition, no statistical difference in the application of
early or late HFOV by the institution was seen (P  .06).
Table 1. Demographics Assess by Survival Status to Pediatric ICU Discharge
Variable All HFOV (N  85) Survivors (n  20) Nonsurvivors (n  65) P
Female subjects 43 (50.6%) 14 (70.0%) 29 (44.6%) .047
Age at pediatric ICU admit, y 6.8 (1.6–14.8) 8.5 (1.5–14.8) 6.5 (1.7–14.8) .69
Race
Caucasian 51 (60.0%) 12 (60.0%) 39 (60.0%)
African American 8 (9.4%) 2 (10.0%) 6 (9.2%)  .99
Asian 5 (5.9%) 1 (5.0%) 4 (6.2%)
Other 18 (21.2%) 4 (20.0%) 14 (21.5%)
Unknown 3 (3.5%) 1 (5.0%) 2 (3.1%)
First transplant 75 (88.2%) 18 (90.0%) 57 (87.7%)  .99
Type of transplant
Bone marrow 34 (40.0%) 8 (40.0%) 26 (40.0%) .23
Cord blood 43 (50.6%) 12 (60.0%) 31 (47.7%)
Peripheral blood 8 (9.4%) 8 (12.3%)
Related donor 16 (18.8%) 4 (20.0%) 12 (18.5%)  .99
Underlying oncology diagnosis 47 (55.3%) 14 (70.0%) 33 (50.8%) .13
Reason for transplant
Acute lymphoblastic leukemia 23 (27.1%) 10 (50.0%) 13 (20.0%) .008
Acute myeloid leukemia 21 (24.7%) 4 (20.0%) 17 (26.2%) .77
Immunodeficiency 8 (9.4%) 3 (15.0%) 5 (7.7%) .38
Hemophagocytic lymphohistiocytosis 8 (9.4%) 0 (0%) 8 (12.3%) .19
Bone marrow failure 8 (9.4%) 1 (5.0%) 7 (10.8%) .67
Metabolic syndrome 10 (11.8%) 2 (10.0%) 8 (12.3)  .99
Hemoglobinopathies 2 (2.4%) 0 (0%) 2 (3.1%)  .99
Lymphomas 1 (1.2%) 0 (0%) 1 (1.5%)  .99
Myelodysplastic 1 (1.2%) 0 (0%) 1 (1.5%)  .99
Myeloproliferative 1 (1.2%) 0 (0%) 1 (1.5%)  .99
Other 2 (2.4%) 0 (0%) 2 (3.1%)  .99
Positive respiratory culture 39 (45.9%) 7 (35.0) 32 (49.2%) .26
Duration of conventional mechanical ventilation prior to HFOV, d 1.0 (0.0–5.0) 0.0 (0.0–1.5) 2.0 (0.0–9.0) .002
Duration of HFOV, d 5.0 (2.0–9.0) 5.0 (2.0–8.0) 4.0 (1.0–11.0) .93
Inhaled nitric oxide 35 (41.2%) 3 (15.0%) 32 (49.2%) .007
NIV prior to invasive mechanical ventilation 46 (54.1%) 10 (50.0%) 36 (55.4%) .67
Renal replacement therapy 33 (38.8%) 7 (35.0%) 26 (40.0%) .69
Vasopressors/inotropes 70 (82.4%) 16 (80.0%) 54 (83.1%) .75
Data are presented as median (interquartile range) and were compared using Wilcoxon rank-sum test, or as frequency (%) and compared using chi-square or Fisher exact tests where appropriate.
HFOV  high-frequency oscillatory ventilation
NIV  noninvasive ventilation
Table 2. Starting Settings on HFOV Compared by Survival Status
HFOV Setting All Survivors Nonsurvivors P
Mean airway pressure, cm H2O 32 (28–36) 32 (25–35) 32 (28–36) .46
Hertz 6 (5–8) 6 (5–9) 6 (5–8) .91
Amplitude, cm H2O 65 (52–74) 58 (45–70) 65 (52–74) .58
Data are presented as medians with interquartile ranges. Survivors were compared to nonsurvivors using a Wilcoxon rank-sum test.
HFOV  high-frequency oscillatory ventilation
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Conventional Mechanical Ventilation Versus Early
HFOV Versus Late HFOV in Subjects With Severe
Pediatric ARDS
Of the 129 subjects included in this comparative anal-
ysis, 50 were in the early HFOV group, 33 were in the
late HFOV group, and 46 were in the conventional me-
chanical ventilation group. The conventional mechani-
cal ventilation group represents the cohort that had se-
vere pediatric ARDS according to the PALICC definition
and did not transition to HFOV. Two subjects were
excluded from the early HFOV group because they had
only moderate pediatric ARDS at time of conversion to
HFOV. Both of these subjects survived. There was a
difference in age among these groups (P  .006). On
pairwise testing, those ventilated with only conventional
mechanical ventilation were older than those in the late
HFOV group (P  .003), but there was no statistical
difference with early HFOV. There was no difference in
gender, oncology diagnosis, source of hematopoietic cell
transplant, or related donor status between the 3 groups
(Table 5).
There was a trend toward a lower survival rate in the
late HFOV group (P  .08), with the early HFOV group
having the highest rate of survival at 30.0% (Table 5). The
duration of mechanical ventilation was different between
groups (P  .03), but on pairwise testing there was no
difference in the total duration of mechanical ventilation
between the conventional mechanical ventilation and early
HFOV groups. Those ventilated with late HFOV had a
longer duration of mechanical ventilation compared to the
early HFOV group (P .039). Ventilator-free days at 28 d
was examined. The distribution of ventilator-free days was
statistically different; however, the median number of ven-
tilator-free days for all groups was 0 (Table 5). Interest-
ingly, in the late HFOV group, every subject had 0 ven-
tilator-free days. In the conventional mechanical ventilation
group, 83% of subjects (n  39) had 0 ventilator-free
days, and in the early HFOV group, 72% of subjects (n36)
had 0 ventilator-free days. On pairwise analysis, ventila-
tor-free days for the conventional mechanical ventilation
was not statistically different from ventilator-free days
for the early HFOV group, but ventilator-free days for
the early HFOV group was different from that of the
late HFOV group (P  .002). The use of noninvasive
ventilation prior to intubation was similar (P  .51).
Vasoactive medication use was common in all groups
and was not statistically different (P  .15). The use of
renal replacement therapy was also not different among
groups (P  .37).
Table 3. Oxygenation Index and Oxygen Saturation Index Over Time Assessed by Pediatric ICU Survival Status
Time on HFOV 6 h Prior Start 6 h 24 h 48 h Stop
Oxygenation Index
Survivors 26.5 (6.4–46.6) 25.6 (21.1–36.8) 23.3 (17.8–32.5) 18.7 (10.7–24.2) 10.7 (7.9–20.1) 6.1 (4.0–9.5)
Nonsurvivors 25.6 (14.0–32.9) 37.2 (26.5–52.2) 32.9 (19.7–48.3) 21.5 (15.6–31.5) 21.5 (13.9–28.0) 20.9 (10.5–48.0)
P .97 .046 .07 .29 .02  .001
Oxygen Saturation Index
Survivors 17.1 (17.0–22.5) 28.3 (23.2–31.5) 18.2 (14.1–27.8) 14.4 (12.0–20.3) 10.5 (9.4–14.8) 5.8 (4.7–9.2)
Nonsurvivors 19.9 (11.2–26.8) 32.5 (27.5–38.7) 25.7 (21.1–34.3) 19.3 (15.6–28.1) 16.0 (12.3–21.8) 17.9 (8.6–38.9)
P .545 .050 .07 .12 .03  .001
Data are presented as medians (interquartile range). Start values were obtained at the time point closest to initiating high-frequency oscillatory ventilation (HFOV).
Table 4. Comparison of Common Critical Care Interventions and Duration of Ventilation by Survivor Status
Interventions and Duration Entire Cohort Survivors Nonsurvivors P
Use of inhaled nitric oxide 35 (41.2%) 3 (15.0%) 32 (49.2%) .007
Identified respiratory pathogen 39 (45.9%) 7 (35.0%) 32 (49.2%) .26
Renal replacement therapy 33 (38.8%) 7 (35.0%) 23 (40.0%) .69
Vasoactive agents 70 (82.4%) 16 (80.0%) 54 (83.1%) .75
Duration of invasive mechanical ventilation, d 16.0 (8.0–26.0) 14.0 (9.0–24.0) 17.0 (7.0–26.0) .87
Duration of HFOV, d 5.0 (2.0–9.0) 5.0 (2.0–8.0) 4.0 (1.0–11.0) .93
Duration of invasive mechanical ventilation prior to HFOV, d 1.0 (0–5.0) 0.0 (0–1.5) 2.0 (0–9.0) .002
Data are presented as medians (interquartile range) and were compared using Wilcoxon rank sum test, or as frequency (%) and compared using chi-square or Fisher exact tests where appropriate.
HFOV  high-frequency oscillatory ventilation
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Discussion
Our study has 3 significant findings. The first is that
subjects who were transitioned to HFOV earlier in the
course of invasive mechanical ventilation had improved
survival when compared to subjects transitioned to HFOV
late in their course of mechanical ventilation. Second, those
who survived continued to have improvement in their
oxygenation; those who died had a plateau in the improve-
ment of their OI at 48 h. The last finding in this cohort is
that the outcomes were not statistically different when
comparing subjects with severe pediatric ARDS who were
managed with conventional mechanical ventilation alone
to those who were transitioned early to HFOV.
HFOV has been a longstanding tool in the treatment of
pediatric ARDS. After HFOV demonstrated a decrease in
the risk of chronic lung disease in premature babies, HFOV
gained interest for use in pediatric ARDS.18 Arnold et al11
found promising results with the application of HFOV in
ARDS, illustrating improved oxygenation and decreased
need for supplemental O2 at 30 d. However, there was no
difference in the duration of mechanical ventilation or sur-
vival. Multiple studies have shown that HFOV can im-
prove oxygenation.12-14,19-21 Despite this improvement in
oxygenation, studies have not confirmed a mortality dif-
ference. Like our study, however, Arnold et al19 found in
a heterogeneous population that an improvement in OI
discriminated between survivors and nonsurvivors, and Ye-
hya et al22 found the same in immunocompromised
subjects.
When comparing subjects on HFOV, most had an im-
provement in oxygenation, but those who survived had a
more dramatic and sustained OI improvement. In this high-
acuity cohort, continued oxygenation improvement was
associated with survival. It is likely that the continued
improvement in oxygenation represents recoverable lung
injury, whereas subjects who experienced a plateau in their
OI improvement may have had unrecoverable lung dam-
age. While the nonsurvivors did have a lower OI at 48 h
and at the conclusion of HFOV, it was not a clinically
notable improvement. The median OI at both points re-
mained consistent with oxygenation criteria for severe pe-
diatric ARDS. A greater use of inhaled nitric oxide was
seen in the nonsurvivor population. This likely reflects the
severity of lung disease in nonsurvivors. Potentially this
rescue intervention was applied more often in this group
due to the lack of sustained improvement in oxygenation.
With this demonstration of improvement in oxygenation,
the critical care community has sought to find the best way
to apply this modality. The improvement in oxygenation is
encouraging, but the lack of clinically relevant positive
changes in outcomes continues to be a source of frustra-
tion. In this cohort, early application of HFOV (ie, within
the first 2 d of invasive mechanical ventilation) was asso-
ciated with improved survival compared to late application
of HFOV. This is in line with suggestions from previously
published literature.12,13 Perhaps this early approach with
HFOV allows for earlier, more aggressive lung recruit-
ment. However, this directly contradicts more recent lit-
erature that questions the current approach to HFOV, sug-
Table 5. Comparison of Demographic and Critical Care Variables Stratified by Mechanical Ventilation Practice
Variable Conventional Mechanical Ventilation (n  46) Early HFOV (n  50)* Late HFOV (n  33) P
Age, y 12.3 (5.2–16.9) 9.8 (2.6–15.3) 3.2 (0.9–10.5) .006
Female subjects 22 (47.8%) 22 (44.0%) 19 (57.6%) .47
Oncology Diagnosis 23 (50.0%) 30 (60.0%) 15 (45.5%) .39
Hematopoietic cell transplant source
Bone Marrow 23 (50.0%) 15 (30.0%) 18 (54.5%) .07
Cord Blood 16 (34.8%) 28 (56.0%) 14 (42.4%)
Peripheral Blood 7 (15.2%) 7 (14.0%) 1 (3.0%)
Related Donor 6 (13.0%) 8 (16.0%) 8 (24.2%) .41
NIV prior to intubation 26 (56.5%) 28 (56.0%) 17 (52.5%) .89
Vasoactive agents 43 (93.5%) 42 (84.0%) 26 (78.8%) .15
Renal replacement therapy 20 (44.4%)† 22 (44.0%) 10 (30.3%) .37
Length of pediatric ICU stay, d 20.0 (9.0–41.0) 18.0 (10.0–30.0) 20.0 (14.0–43.0) .19
Mechanical ventilation, d 11.5 (3.0–27.0) 11.5 (5.0–19.0) 18.0 (13.0–30.0) .030
Ventilator-free days at 28 d 0 (0–0) 0 (0–11) 0 (0–0) .004
Survival 11 (23.9%) 15 (30.0%) 3 (9.1%) .08
Data are presented as medians (interquartile range) and were compared using Kruskal-Wallis test, or as frequency (%) and compared using an extended Fisher exact test.
* 2 subjects were excluded from the early HFOV group because they were started on HFOV when they had moderate pediatric ARDS.
† 1 subject was missing data regarding renal replacement therapy from this group.
HFOV  high-frequency oscillatory ventilation
NIV  noninvasive ventilation
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gesting that it is associated with worse mortality and longer
duration of mechanical ventilation in the general pediatric
population.15,16 In the study by Bateman et al,15 ventilator-
free days were lower in the early HFOV cohort as com-
pared to those who were managed with only conventional
mechanical ventilation or with late HFOV. This study’s
cohort is unique from the general pediatric population in
that they were at higher risk for a variety of lung diseases,
including severe infections, diffuse alveolar hemorrhage,
idiopathic pulmonary syndrome, lung graft-versus-host dis-
ease, and bronchiolitis obliterans.6,8,23 The recoverability
of each of these diseases is variable. Additionally, these
patients have generally been exposed to previous lung-
toxic drugs and infections, which placed them at risk to be
admitted to the pediatric ICU with existing lung disease.
Therefore, the findings from studies of the general pedi-
atric population may not be applicable to our unique and
highly vulnerable patient population.
To begin to understand the effectiveness of HFOV com-
pared to conventional mechanical ventilation, we isolated
subjects with severe pediatric ARDS, as defined by
PALICC guidelines, treated with conventional mechanical
ventilation alone and compared them to the early and late
HFOV groups. In this analysis, we found data that con-
tradict previously published data by Bateman et al.15 In
this secondary analysis of the RESTORE database, they
found that those treated with early HFOV had a longer
duration of mechanical ventilation. In our specialized co-
hort, this was not the case. Those treated with early HFOV
had the same duration of mechanical ventilation as those
with severe pediatric ARDS treated with conventional me-
chanical ventilation alone. Additionally, the early HFOV
group had the highest survival at 30%, although this did
not meet statistical significance. Isolating those treated
with HFOV later in the course of mechanical ventilation,
we found this group to have both a higher mortality and a
longer duration of mechanical ventilation.
Our study does have limitations that are inherent to all
retrospective analyses. We were limited by the availability
of the data, particularly blood gas data, to calculate OI for
every subject at each time point. We hoped to negate some
of this limitation by collecting OI at multiple time points
to obtain a more complete picture of the degree of oxy-
genation failure in this population. Additionally, the study
is limited by a diverse approach to both transitioning and
utilization of HFOV. Because this study was retrospective,
subjects were transitioned to HFOV at the discretion of the
clinical care team. Despite these limitations, this study is
strengthened by the large cohort of subjects from multiple
centers, which improves the generalizability and the fre-
quency of ventilator and blood gas data collected through-
out the study.
Conclusion
In pediatric allogeneic hematopoietic cell transplant sub-
jects, those treated with HFOV had a lower overall pedi-
atric ICU survival at 23.5% compared to the reported sur-
vival rates of 40–50% of those receiving all types of
mechanical ventilation.5,24,25 However, this is more likely
a reflection of the severity of lung injury than of the mo-
dality itself. Furthermore, there is a suggestion that early
application of HFOV may be of benefit. A prospective
study is necessary to answer the questions about the timing
of HFOV and the overall benefit of this modality. While it
is clear that a prospective trial is warranted to make firm
recommendations, our data suggest that the late use of
HFOV in this population, especially after 7 d of conven-
tional mechanical ventilation, should be undertaken with
caution.
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